646P A phase I trial of AVA6000, a fibroblast activation protein (FAP)-released, tumor microenvironment (TME)-targeted doxorubicin peptide drug conjugate in patients with FAP-positive solid tumors

Saved in:
Bibliographic Details
Published inAnnals of oncology Vol. 35; p. S511
Main Authors Twelves, C.J., Banerji, U., Tap, W.D., Cook, N., Evans, T.R.J., Plummer, R., Anthoney, A., Plummer, C., Dawson, R., Loadman, P., Lahu, G., Jones, H., Kinnersley, N., Edwards, R., Gordon, G., Cranmer, L.D.
Format Journal Article
LanguageEnglish
Published Elsevier Ltd 01.09.2024
Online AccessGet full text

Cover

More Information
ISSN:0923-7534
DOI:10.1016/j.annonc.2024.08.712